Sundia MediTech has entered into a strategic alliance for contract research and manufacturing services (CRAMS) in mainland China with ScinoPharm (Changshu) Pharmaceuticals.
Set up in 2004 and based in Shanghai, Sundia MediTech is a leading Chinese clinical research organisation (CRO) offering global drug discovery and development services, with a particular focus on chemistry synthesis and preclinical studies.
ScinoPharm (Changshu) Pharmaceuticals is a subsidiary of ScinoPharm Taiwan, which provides process R&D and active pharmaceutical ingredient (API) manufacturing services to industry worldwide.
It was founded in 2009 and operates out of the Changshu Economic Development Zone in Jiangsu Province.
Single-source solutions
The two companies will combine resources to establish “a robust collaboration with single-source solutions to address the increasing number of multinational companies shifting their drug-development research and clinical trials in China”, explained Dr Jo Shen, chief executive officer of ScinoPharm Taiwan and chairman of ScinoPharm Changshu.
Sundia’s diversified technical know-how and capabilities in research and development for new medicines will be yoked to ScinoPharm’s expertise in process R&D and commercial production, especially for highly potent oncology APIs.
CRAMS destination
China is among the first-choice CRAMS destinations in Asia and is likely to witness substantial growth as global R&D expenditure shifts increasingly to outsourcing, the partners noted.
In addition to process R&D and commercial production for generic APIs, ScinoPharm offers an interactive, single-location custom-synthesis service, spanning the entire R&D chain from initial development to product launch.
The company also provides product-registration, regulatory-filing and Good Manufacturing Practice (GMP)-inspection support to both domestic and overseas clients.
